Advertisement

CA 125 in gynecologic practice

  • George D. Malkasian Jr.
    Correspondence
    Reprint requests: George D. Malkasian, Jr., M.D., Department of Obstetrics and Gynecology, Mayo Clinic, 200 1 st St. SW, Rochester, MN 55905.
    Affiliations
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota USA

    the Microbiology Research Laboratory, Mayo Clinic, Rochester, Minnesota USA

    the Gynecologic Oncology Laboratories, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts USA

    Harvard Medical School, Boston, Massachusetts USA

    Centocor, Malvern, Pennsylvania USA
    Search for articles by this author
  • Karl C. Podratz
    Affiliations
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota USA

    the Microbiology Research Laboratory, Mayo Clinic, Rochester, Minnesota USA

    the Gynecologic Oncology Laboratories, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts USA

    Harvard Medical School, Boston, Massachusetts USA

    Centocor, Malvern, Pennsylvania USA
    Search for articles by this author
  • C.Robert Stanhope
    Affiliations
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota USA

    the Microbiology Research Laboratory, Mayo Clinic, Rochester, Minnesota USA

    the Gynecologic Oncology Laboratories, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts USA

    Harvard Medical School, Boston, Massachusetts USA

    Centocor, Malvern, Pennsylvania USA
    Search for articles by this author
  • Roy E. Ritts Jr.
    Affiliations
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota USA

    the Microbiology Research Laboratory, Mayo Clinic, Rochester, Minnesota USA

    the Gynecologic Oncology Laboratories, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts USA

    Harvard Medical School, Boston, Massachusetts USA

    Centocor, Malvern, Pennsylvania USA
    Search for articles by this author
  • Vincent R. Zurawski Jr.
    Affiliations
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota USA

    the Microbiology Research Laboratory, Mayo Clinic, Rochester, Minnesota USA

    the Gynecologic Oncology Laboratories, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts USA

    Harvard Medical School, Boston, Massachusetts USA

    Centocor, Malvern, Pennsylvania USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Serum CA 125 levels were determined in 64 women with benign ovarian lesions, 92 women with uterine fundal lesions, and six patients who had negative second-look laparotomy for epithelial ovarian carcinoma. Of those with benign lesions, 13 of 31 patients with endometriosis had levels >35 U/ml. Six of 34 patients with endometrial carcinoma had elevated levels before the primary operation, and six of 15 patients with recurrent endometrial carcinoma had elevated levels. The six ovarian cancer patients had had negative findings at second look 7 to 40 months before recurrence. Where close serial levels were available, the level became elevated 2 to 5 months before clinically apparent recurrent disease was noted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kohler G
        • Milstein C
        Continuous cultures of fused cells secreting antibody of predefined specificity.
        Nature. 1975; 256: 495
        • Bast Jr, RC
        • Feeney M
        • Lazarus H
        • Nadler LM
        • Colvin RB
        • Knapp RC
        Reactivity of a monoclonal antibody with human ovarian carcinoma.
        J Clin Invest. 1981; 68: 1331
        • Kabawat SE
        • Bast Jr, RC
        • Welch WR
        • Knapp RC
        • Colvin RB
        Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.
        Am J Clin Pathol. 1983; 79: 98
        • Klug TL
        • Bast Jr, RC
        • Niloff JM
        • Knapp RC
        • Zurawski Jr, VR
        Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas.
        Cancer Res. 1984; 44: 1048
        • Niloff JM
        • Knapp RC
        • Schaetzl E
        • Reynolds C
        • Bast Jr, RC
        CA125 antigen levels in obstetric and gynecologic patients.
        Obstet Gynecol. 1984; 64: 703
        • Ricolleau G
        • Fumoleau P
        • Kremer M
        • Curtet C
        • Douillard JY
        • Chatal JF
        Advances in cancer research [Abstract].
        in: Stockholm, Sweden: International Society for Oncodevelopmental Biology and Medicine, eleventh annual meeting. September, 1983
        • Bast RC
        • Klug TL
        • St John E
        • et al.
        A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
        N Engl J Med. 1983; 309: 883
      1. Lavin PT, Knapp RC, Niloff JM, et al. CA125 for the monitoring of ovarian cardinoma during primary therapy. Obstet Gynecol (in press).

        • Niloff JM
        • Bast Jr, RC
        • Schaetzl E
        • Knapp RC
        Predictive value of CA125 antigen levels in second-look procedures for ovarian cancer.
        Am J Obstet Gynecol. 1985; 151: 981
        • Berek JS
        • Knapp RC
        • Malkasian Jr, GD
        • et al.
        CA125 serum levels correlate with second-look operations among ovarian cancer patients: a prospective multi-institutional study.
        Obstet Gynecol. 1986; 67: 685
        • Niloff JM
        • Klug TL
        • Schaetzl E
        • Zurawski VR
        • Knapp RC
        • Bast Jr, RC
        Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix.
        Am J Obstet Gynecol. 1984; 148: 1057
        • American Fertility Society
        Classification of endometriosis.
        Fertil Steril. 1979; 32: 633
        • Barbieri RL
        • Niloff JM
        • Bast Jr, RC
        • Schaetzl E
        • Kistner RW
        • Knapp RC
        Elevated serum concentrations of CA125 in patients with advanced endometriosis.
        Fertil Steril. 1986; 46: 767
        • Einhorn H
        • Bast Jr, RC
        • Knapp RC
        • Tjernberg B
        • Zurawski Jr, VR
        Preoperative evaluation of serum CA125 levels in patients with primary epithelial ovarian cancer.
        Obstet Gynecol. 1986; 67: 414
        • Podratz KC
        • Malkasian Jr, GD
        • Hilton JF
        • Harris EA
        • Gaffey TA
        Second-look laparotomy in ovarian cancer.
        Am J Obstet Gynecol. 1985; 152: 203